<DOC>
	<DOCNO>NCT01601002</DOCNO>
	<brief_summary>Patients episode depression late life prescribe mirtazapine recruit clinical sample monitor weight receive blood test usual course treatment determine polymorphism specific gene ( LEPR ) think affect weight gain .</brief_summary>
	<brief_title>LEPR Polymorphism Weight Gain Mirtazapine Late Life Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Weight Gain</mesh_term>
	<mesh_term>Mirtazapine</mesh_term>
	<mesh_term>Mianserin</mesh_term>
	<criteria>patient older 50 year meet criterion diagnosis major depressive disorder ( DSM IV code 296.2x 296.3x ) confirm score &gt; 20 HAMD 24 item scale structure clinical interview use SCID consultant psychiatrist Treatment resistant depression ( defined failure respond â‰¥2 adequate antidepressant trial ) Major depressive disorder psychosis ( 296.x4 ) Those depression fulfill chronic specifier ( MDE &gt; 2 year ) Significant Axis II pathology Previous trial mirtazapine Concurrent antipsychotic usage Comorbid dementia ( confirm MMSE &lt; 24 ) Substance misuse include drug and/or alcohol dependence/abuse past 3 month Bipolar disorder Schizophrenia Obsessive compulsive disorder Post traumatic stress disorder Eating disorder Head injury Recent stroke ( &lt; 3 month ) Recent MI ( &lt; 3 month ) Currently actively participate structured/formal psychotherapy Being non ambulatory Those actively suicidal Those incapable informed consent</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Mirtazapine</keyword>
</DOC>